ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 11 JANUARY 2024 at…
VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…
Oslo, Norway, 11 January 2024 Norwegian pharmaceutical company Vistin Pharma ASA (“Vistin Pharma”) announced today that the Board has decided for…
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is…
- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality…
SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2024,…
DUBLIN, IRELAND / ACCESSWIRE / January 10, 2024 / Nemysis Ltd and Kolinpharma® SpA ("Kolinpharma®") are pleased to announce they…
Collaboration streamlines patient access to oncology clinical trials; further expands Parexel's Site Alliance Network across Asia/PacificDURHAM, N.C. and TOKYO, Jan. 10,…
WESTON, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company…
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced…